Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/168449
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma |
Autor: | Donk, Niels W. C. J. van de; Moreau, Philippe; Plesner, Torben; Palumbo, Antonio; Gay, Francesca; Laubach, Jacob P.; Malavasi, Fabio; Avet-Loiseau, Hervé; Mateos, Maria Victoria; Sonneveld, Pieter; Lokhorst, Henk M.; Richardson, Paul G. | Fecha de publicación: | 2016 | Editor: | American Society of Hematology | Citación: | Blood 127(6): 681-695 (2016) | Resumen: | Immunotherapeutic strategies are emerging as promising therapeutic approaches in multiple myeloma (MM), with several monoclonal antibodies in advanced stages of clinical development. Of these agents, CD38-targeting antibodies have marked single agent activity in extensively pretreated MM, and preliminary results from studies with relapsed/refractory patients have shown enhanced therapeutic efficacy when daratumumab and isatuximab are combined with other agents. Furthermore, although elotuzumab (anti-SLAMF7) has no single agent activity in advancedMM, randomized trials in relapsed/refractory MM have demonstrated significantly improved progression-free survival when elotuzumabis added to lenalidomide-dexamethasone or bortezomib-dexamethasone. Importantly, there has been no significant additive toxicity when these monoclonal antibodies are combined with other anti-MM agents, other than infusion-related reactions specific to the therapeutic antibody. Prevention and management of infusion reactions is important to avoid drug discontinuation, which may in turn lead to reduced efficacy of anti- MM therapy. Therapeutic antibodies interfere with several laboratory tests. First, interference of therapeutic antibodies with immunofixation and serum protein electrophoresis assays may lead to underestimation of complete response. Strategies to mitigate interference, based on shifting thetherapeutic antibody band, are in development. Furthermore, daratumumab, and probably also other CD38-targeting antibodies, interfere with blood compatibility testing and thereby complicate the safe release of blood products. Neutralization of the therapeutic CD38 antibody or CD38 denaturation on reagent red blood cells mitigates daratumumab interference with transfusion laboratory serologic tests. Finally, therapeutic antibodies may complicate flow cytometric evaluation of normal and neoplastic plasma cells, since the therapeutic antibody can affect the availability of the epitope for binding of commercially available diagnostic antibodies. | URI: | http://hdl.handle.net/10261/168449 | DOI: | 10.1182/blood-2015-10-646810 | Identificadores: | doi: 10.1182/blood-2015-10-646810 e-issn: 1528-0020 issn: 0006-4971 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
79
checked on 22-abr-2024
SCOPUSTM
Citations
165
checked on 23-abr-2024
WEB OF SCIENCETM
Citations
149
checked on 23-feb-2024
Page view(s)
341
checked on 24-abr-2024
Download(s)
80
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.